Adicet Bio
Adicet Bio
ACET
NASDAQ
0.80
USD
2.56%
About
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL).
Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 370.4K |
| Three Month Average Volume | 20.2M |
| High Low | |
| Fifty-Two Week High | 3.77 USD |
| Fifty-Two Week Low | 1.05 USD |
| Fifty-Two Week High Date | 09 Jan 2024 |
| Fifty-Two Week Low Date | 03 Jul 2024 |
| Price and Volume | |
| Current Price | 1.46 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.03% |
| Thirteen Week Relative Price Change | -5.92% |
| Twenty-Six Week Relative Price Change | -44.67% |
| Fifty-Two Week Relative Price Change | -41.74% |
| Year-to-Date Relative Price Change | -34.77% |
| Price Change | |
| One Day Price Change | -1.35% |
| Thirteen Week Price Change | 0.69% |
| Twenty-Six Week Price Change | -39.17% |
| Five Day Price Change | -2.01% |
| Fifty-Two Week Price Change | -27.00% |
| Year-to-Date Price Change | -22.75% |
| Month-to-Date Price Change | -3.31% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.93283 USD |
| Book Value Per Share (Most Recent Quarter) | 2.85326 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.93283 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.85326 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.89861 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.31436 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.52806 USD |
| Normalized (Last Fiscal Year) | -2.8622 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.31436 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.52806 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.31436 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.52806 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.691 USD |
| Cash Per Share (Most Recent Quarter) | 2.71925 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.17264 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.04252 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.44739 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -647 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -753.98% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -780.40% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -748.46% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -31.46% |
| Tangible Book Value (5 Year) | 10.31% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 65.27% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 56.26% |
| EPS Change (Trailing Twelve Months) | 6.42% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -224,069,000 |
| Net Debt (Last Fiscal Year) | -159,711,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 13 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -98,181,000 |
| Free Cash Flow (Trailing Twelve Months) | -92,578,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -53.03% |
| Return on Assets (Trailing Twelve Months) | -50.25% |
| Return on Assets (5 Year) | -37.03% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -61.69% |
| Return on Equity (Trailing Twelve Months) | -57.91% |
| Return on Equity (5 Year) | -50.36% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -57.18% |
| Return on Investment (Trailing Twelve Months) | -53.87% |
| Return on Investment (5 Year) | -40.28% |